Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
J Natl Compr Canc Netw. 2013 Jan 1;11(1):43-9. doi: 10.6004/jnccn.2013.0007.
Many advances were made in the treatment of multiple myeloma since the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib. An increasing number of clinical trials have examined consolidation/maintenance therapy as part of a sequential approach after induction therapy and demonstrated benefit in patients eligible and ineligible for transplantation. This outcome improvement reported with consolidation/maintenance therapy should be balanced against the toxicity profile, and prompt management of adverse events is necessary. This article provides an overview of the main trials including consolidation/maintenance therapy after induction for transplant-ineligible patients. Recommendations on how to manage treatment-related toxicities are also provided.
自免疫调节药物沙利度胺和来那度胺以及蛋白酶体抑制剂硼替佐米问世以来，多发性骨髓瘤的治疗取得了许多进展。越来越多的临床试验将巩固/维持治疗作为诱导治疗后的序贯治疗的一部分进行了检查，并在适合和不适合移植的患者中显示出获益。与巩固/维持治疗相关的这种改善的结果应与毒性特征相平衡，并且需要及时管理不良事件。本文概述了主要试验，包括不适合移植患者的诱导后巩固/维持治疗。还提供了有关如何管理治疗相关毒性的建议。
